Business
Bloomios Begins Trading on OTCQB Venture Market as BLMS, as Hemp-Derived Cannabinoid Product Sales Exceed $8 million
Bloomios Begins Trading on OTCQB Venture Market as BLMS, as Hemp-Derived Cannabinoid Product Sales Exceed $8 million.
About this update from Bloomios Inc.
[{"type":"text","content":"\n\n\n\nBloomios Begins Trading on OTCQB Venture Market as BLMS, as Hemp-Derived Cannabinoid Product Sales Exceed $8 million\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nBloomios Begins Trading on OTCQB Venture Market as BLMS, as Hemp-Derived Cannabinoid Product Sales Exceed $8 million\nPR Newswire\nSANTA BARBARA, Calif., March 15, 2022\n\n\n\nSANTA BARBARA, Calif., March 15, 2022 /PRNewswire/ -- Bloomios, Inc. (OTCQB: BLMS), a leading researcher, manufacturer and wholesaler of hemp-derived cannabinoid nutraceuticals and cosmetics, will begin trading on the OTCQB® Venture Market under the symbol, BLMS, at the opening of the market today.\n\n \n \n \n \n \n \n\n \nOver the course of the past year, Bloomios has rapidly emerged as a premier manufacturer of private- and white-label hemp-derived cannabinoid products. This includes nutraceuticals and cosmetics that incorporate cannabidiol (CBD), the most popular cannabinoid of the more than 100 distinct cannabinoids that can be derived from hemp.\nBloomios also produces products featuring such alternative cannabinoids and peripheral components of hemp which share similar health benefits with CBD, like cannabigerol (CBG) for pain management and cannabinol (CBN) for sleep, as well as terpenes (or flavonoids) that create a beneficial entourage effect for the user.\nSince Bloomios' official launch in the fourth quarter of 2020, gross revenues have climbed from virtually zero to total more than $8 million by September 30, 2021, with demand exceeding supply. \nFollowing a facility expansion and equipment upgrade, Bloomios has increased its production capacity by an estimated 300%. Bloomios products are now being distributed by hundreds of corporate customers across the U.S.\n\"As a fully-reporting, emerging growth company, our listing on the OTCQB greatly elevates our profile in the market, provides greater liquidity and helps broaden our shareholder base,\" stated Bloomios CEO, Michael Hill. \"The listing represents a major step in our long-term capital market strategy designed to build shareholder value and ...